Also known as: Neuronal Ceroid Lipofuscinosis, NCL, juvenile neuronal ceroid lipofuscinosis
Juvenile-onset form (most common) typically presents ages 4-8 with vision loss, progressing to seizures and cognitive decline. Other forms present at different ages. Affects males and females equally.
Gene therapy for Batten disease (CLN2) has FDA approval for intracerebroventricular infusion in early-stage juvenile neuronal ceroid lipofuscinosis. Other clinical trials are evaluating gene therapy for other Batten disease subtypes. Early diagnosis through genetic testing is critical, as gene therapy benefits are greater with earlier treatment before extensive neuronal damage. The Batten Disease Support and Research Association provides comprehensive trial information and patient support. If Batten disease is diagnosed, discuss with your neurologist about gene therapy eligibility and timing of treatment initiation.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...